Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306247913> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4306247913 endingPage "196" @default.
- W4306247913 startingPage "183" @default.
- W4306247913 abstract "Despite approval of B-cell lymphoma (BCL)-2 inhibitor venetoclax for certain hematologic malignancies, its broader clinical benefit is curtailed by resistance. Our study aimed to determine if treatment with novel anticancer agents targeting BCL-2 and mouse double minute 2 (MDM2) could overcome venetoclax resistance in preclinical models.Venetoclax-sensitive and venetoclax-resistant acute myeloid leukemia (AML) and acute lymphoblastic leukemia cells and xenograft models were used to evaluate antitumor effects and underlying mechanisms associated with combined BCL-2 inhibitor lisaftoclax (APG-2575) and MDM2 inhibitor alrizomadlin (APG-115).The combination exhibited synergistic antiproliferative and apoptogenic activities in TP53 wild-type AML cell lines in vitro. This synergy was further exemplified by deep antitumor responses and prolonged survival in AML cell line-derived and patient-derived xenograft models. Interestingly, the combination treatment resensitized (to apoptosis) venetoclax-resistant cellular and mouse models established via chronic drug exposure or genetically engineered with clinically relevant BCL-2 gene mutations. Synergistic effects in reducing cellular viability and proliferation were also demonstrated in primary samples of patients with venetoclax-resistant AML treated with lisaftoclax and alrizomadlin ex vivo. Mechanistically, alrizomadlin likely primes cancer cells to BCL-2 inhibition-induced cellular apoptosis by downregulating expression of antiapoptotic proteins myeloid cell leukemia-1 and BCL-extra-large and upregulating pro-death BCL-2-associated X protein.Lisaftoclax in combination with alrizomadlin overcomes venetoclax resistance mediated by various mechanisms, including BCL-2 mutations. In addition, we posit further, putative molecular mechanisms. Our data rationalize clinical development of this treatment combination in patients with diseases that are insensitive or resistant to venetoclax." @default.
- W4306247913 created "2022-10-15" @default.
- W4306247913 creator A5007547562 @default.
- W4306247913 creator A5021773274 @default.
- W4306247913 creator A5022301199 @default.
- W4306247913 creator A5027546968 @default.
- W4306247913 creator A5028312727 @default.
- W4306247913 creator A5028456330 @default.
- W4306247913 creator A5051994266 @default.
- W4306247913 creator A5053150001 @default.
- W4306247913 creator A5065668271 @default.
- W4306247913 creator A5074334301 @default.
- W4306247913 creator A5077134386 @default.
- W4306247913 creator A5085723739 @default.
- W4306247913 date "2022-10-14" @default.
- W4306247913 modified "2023-10-18" @default.
- W4306247913 title "Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies" @default.
- W4306247913 cites W4294051571 @default.
- W4306247913 doi "https://doi.org/10.1158/1078-0432.ccr-22-0978" @default.
- W4306247913 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36240005" @default.
- W4306247913 hasPublicationYear "2022" @default.
- W4306247913 type Work @default.
- W4306247913 citedByCount "1" @default.
- W4306247913 countsByYear W43062479132023 @default.
- W4306247913 crossrefType "journal-article" @default.
- W4306247913 hasAuthorship W4306247913A5007547562 @default.
- W4306247913 hasAuthorship W4306247913A5021773274 @default.
- W4306247913 hasAuthorship W4306247913A5022301199 @default.
- W4306247913 hasAuthorship W4306247913A5027546968 @default.
- W4306247913 hasAuthorship W4306247913A5028312727 @default.
- W4306247913 hasAuthorship W4306247913A5028456330 @default.
- W4306247913 hasAuthorship W4306247913A5051994266 @default.
- W4306247913 hasAuthorship W4306247913A5053150001 @default.
- W4306247913 hasAuthorship W4306247913A5065668271 @default.
- W4306247913 hasAuthorship W4306247913A5074334301 @default.
- W4306247913 hasAuthorship W4306247913A5077134386 @default.
- W4306247913 hasAuthorship W4306247913A5085723739 @default.
- W4306247913 hasBestOaLocation W43062479131 @default.
- W4306247913 hasConcept C121608353 @default.
- W4306247913 hasConcept C126322002 @default.
- W4306247913 hasConcept C190283241 @default.
- W4306247913 hasConcept C203014093 @default.
- W4306247913 hasConcept C2777938653 @default.
- W4306247913 hasConcept C2778461978 @default.
- W4306247913 hasConcept C2778729363 @default.
- W4306247913 hasConcept C2779282312 @default.
- W4306247913 hasConcept C2779338263 @default.
- W4306247913 hasConcept C2779675984 @default.
- W4306247913 hasConcept C502942594 @default.
- W4306247913 hasConcept C54355233 @default.
- W4306247913 hasConcept C71924100 @default.
- W4306247913 hasConcept C86803240 @default.
- W4306247913 hasConceptScore W4306247913C121608353 @default.
- W4306247913 hasConceptScore W4306247913C126322002 @default.
- W4306247913 hasConceptScore W4306247913C190283241 @default.
- W4306247913 hasConceptScore W4306247913C203014093 @default.
- W4306247913 hasConceptScore W4306247913C2777938653 @default.
- W4306247913 hasConceptScore W4306247913C2778461978 @default.
- W4306247913 hasConceptScore W4306247913C2778729363 @default.
- W4306247913 hasConceptScore W4306247913C2779282312 @default.
- W4306247913 hasConceptScore W4306247913C2779338263 @default.
- W4306247913 hasConceptScore W4306247913C2779675984 @default.
- W4306247913 hasConceptScore W4306247913C502942594 @default.
- W4306247913 hasConceptScore W4306247913C54355233 @default.
- W4306247913 hasConceptScore W4306247913C71924100 @default.
- W4306247913 hasConceptScore W4306247913C86803240 @default.
- W4306247913 hasFunder F4320319131 @default.
- W4306247913 hasIssue "1" @default.
- W4306247913 hasLocation W43062479131 @default.
- W4306247913 hasLocation W43062479132 @default.
- W4306247913 hasOpenAccess W4306247913 @default.
- W4306247913 hasPrimaryLocation W43062479131 @default.
- W4306247913 hasRelatedWork W2012639655 @default.
- W4306247913 hasRelatedWork W2373572728 @default.
- W4306247913 hasRelatedWork W2753587986 @default.
- W4306247913 hasRelatedWork W2899472109 @default.
- W4306247913 hasRelatedWork W2945426768 @default.
- W4306247913 hasRelatedWork W3012377581 @default.
- W4306247913 hasRelatedWork W3116974172 @default.
- W4306247913 hasRelatedWork W4297564379 @default.
- W4306247913 hasRelatedWork W4320019111 @default.
- W4306247913 hasRelatedWork W4362539513 @default.
- W4306247913 hasVolume "29" @default.
- W4306247913 isParatext "false" @default.
- W4306247913 isRetracted "false" @default.
- W4306247913 workType "article" @default.